Cardiomyopathy
Atrial systole and left ventricular filling in hypertrophic cardiomyopathy: Effect of verapamil

https://doi.org/10.1016/0002-9149(83)90317-XGet rights and content

Abstract

Many patients with hypertrophic cardiomyopathy (HC) have impaired left ventricular (LV) rapid diastolic filling. To quantitate the contribution of atrial systole to LV filling, we used radionuclide angiography to study 30 normal volunteers and 42 patients with HC before and after oral administration of verapamil (320 to 560 mg/day). LV time-activity curves were constructed by combined forward and reverse gating from the R wave, and the onset of atrial systole was determined by the P-R interval. The percent of LV stroke volume filled during rapid diastolic filling and atrial systole was then computed. Peak LV filling rate during rapid diastolic filling was expressed in end-diastolic volume (EDV)/second. Peak rate of rapid diastolic filling was not different in normal patients and those with HC (3.3 ± 0.6 versus 3.3 ± 1.1 EDV/s) and was within the normal range in 34 patients with HC (81%). However, the contribution to LV filling volume by rapid diastolic filling was diminished in patients with HC (83 ± 7% normal, 67 ± 17% HC, p < 0.001) and the contribution of atrial systole was increased (16 ± 8% normal, 31 ± 18% HC, p < 0.001). LV filling volume during atrial systole was above the upper normal limit of 31% in 17 patients (40%), including 13 patients with a normal peak filling rate. After verapamil, peak filling rate increased (to 4.2 ± 1.2 EDV/s, p < 0.001), percent LV filling during rapid diastolic filling increased (to 83 ± 7%, p < 0.001), and percent LV filling during atrial systole decreased (to 16 ± 9%, p < 0.001). Percent LV filling volume during atrial systole was abnormal after verapamil in only 3 patients (7%). Hence, although the peak rate of rapid diastolic filling may be normal in patients with HC, the contribution to LV filling by rapid diastolic filling is reduced and that of atrial systole is thereby increased. Increased rate and magnitude of rapid diastolic filling during verapamil is associated with decrease and normalization of the contribution of atrial systole to LV filling. These data suggest that many patients with HC are at risk of hemodynamic decompensation with the onset of atrial fibrillation or other tachyarrhythmias and loss of the atrial contribution to LV filling. This risk may be reduced during verapamil therapy.

References (22)

  • MG St John Sutton et al.

    Echocardiographic assessment of left ventricular filling and septal and posterior wall dynamics in idiopathic hypertrophic subaortic stenosis

    Circulation

    (1978)
  • Cited by (174)

    • Extent and magnitude of low-voltage areas assessed by ultra-high-density electroanatomical mapping correlate with left atrial function

      2018, International Journal of Cardiology
      Citation Excerpt :

      In a recent consensus statement of the EHRA, AR has been defined as ‘any complex of structural, architectural, contractile or electrophysiological changes affecting the atria with the potential to produce clinically-relevant manifestations’ [1]. AR is independently associated with increased mortality and patient deterioration [2,3] and has been linked to disease progression and arrhythmias (e.g. AF) [4–7]. Current evidence indicates that atrial function extends beyond the classical view of an “atrial kick” to improve ventricular filling [1].

    • Predictors of future onset of atrial fibrillation in hypertrophic cardiomyopathy

      2018, Archives of Cardiovascular Diseases
      Citation Excerpt :

      A series of prospective studies have identified predictors of future AF development in patients with HCM, including age [9], heart failure symptoms [5,10], N-terminal pro B-type natriuretic peptide concentration or P wave dispersion on electrocardiography [11], as well as left atrial (LA) size and phasic function on imaging [9,11]. The mechanism leading to AF in HCM patients is thought to be mediated by atrial remodelling secondary to left ventricular (LV) diastolic dysfunction [12]. However, although comparative studies have reported higher prevalence [13] and burden [14] of LV fibrosis on CMR in HCM patients with AF, a relationship between the ventricular HCM phenotype and AF occurrence has not been confirmed prospectively.

    • Advances in medical treatment of hypertrophic cardiomyopathy

      2014, Journal of Cardiology
      Citation Excerpt :

      Kaltenbach et al. reported that the long-term use of verapamil improved the clinical symptoms and LV function in patients with HOCM [50]. It is acknowledged that verapamil improves LV diastolic function in the early diastolic phase [51–53]. The intracellular Ca2+ concentration of myocytes is known to be very high in patients with HCM, and appears to be related to abnormal LV diastolic dysfunction [54,55].

    • 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology

      2011, Journal of the American College of Cardiology
      Citation Excerpt :

      Possible mechanisms for symptomatic improvement include negative inotropic and rate-lowering effects similar to those of beta blockers. However, the effect of verapamil on diastolic dysfunction is controversial (258–262). Diltiazem has also been shown to improve measures of diastolic performance (263) and to prevent or diminish myocardial ischemia (264).

    View all citing articles on Scopus
    View full text